GlassScriptPhysician profile
Chelsea M Mathis
NPI 1922318641
$4,989.44
in general payments reported to CMS, 2019-2025
24 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $680 · 2023: $974 · 2024: $1,100 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.78 |
| Education | $340.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.28 | 2021-2025 | |
| Janssen Biotech, INC. | $679.50 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $446.29 | 2021-2025 | Ilumya |
| Incyte Corporation | $363.09 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $312.61 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $279.02 | 2021-2025 | |
| Ucb, INC. | $260.33 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.45 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Amgen INC. | $191.76 | 2021-2025 | Otezla, Otezla |
| Botanix Sb INC | $179.32 | 2025 | Sofdra |
| Lilly USA, LLC | $135.34 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $102.41 | 2021-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $93.67 | 2023-2024 | Vtama |
| Pfizer INC. | $84.71 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $83.41 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.27 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $56.28 | 2024-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $51.87 | 2022-2023 | |
| Almirall LLC | $50.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.49 | 2023-2024 | Cyltezo, Spevigo |
| Verrica Pharmaceuticals INC. | $38.38 | 2024-2025 | Ycanth |
| Journey Medical Corporation | $24.98 | 2025 | |
| Vyne Pharmaceuticals INC. | $23.29 | 2021 | |
| Organon LLC | $22.59 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.